A Chinese company has developed a new diabetes drug that could become a strong competitor to Ozempic and Monjauro as a weight loss aid.
Called ecnoglutide, the drug is being developed by the company Hangzhou Sciwind Biosciences and is administered as a weekly injection, just like Ozempic and Monjauro.
According to an article published in the journal The Lancet Diabetes & Endocrinology, the formula proved to be surprisingly effective in patients who took part in the final stage of clinical trials.
According to the study, these patients lost more than 15% of their weight after 48 weeks. Additionally, the research revealed that 93% of the patients who underwent testing lost at least 5% of their weight.
In addition to aiding weight loss, the medication also proved effective in improving blood pressure and reducing liver fat.
Hangzhou Sciwind Biosciences hopes the drug will be approved by early 2026. Once approved, it could be exported to other countries and directly compete with Ozempic and Monjauro.
Photo and video: Unsplash. This content was created with the help of AI and reviewed by the editorial team.
